Joint Formulary & PAD

Saxagliptin - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Existing patients would not be expected to change therapy unless appropriate to do so.

PAD Profile

ChemicalSubstance :
Saxagliptin
Indication :
Diabetes Mellitus
Group Name :
Keywords :
Gliptins, DPP-4, Dipeptylpeptidase -4 inhibitor, Type II
Brand Names Include :
Onglyza
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5

Other Indications

Below are listed other indications that Saxagliptin is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee recommend:

sitagliptin (prescribed generically) as the preferred gliptin (DPP4) - GREEN traffic light status

linagliptin RESTRICTED USE - as an option in patients with deteriorating renal function where there is a risk that dose reduction of sitagliptin may not take place

Other gliptins (alogliptin, vildagliptin, saxagliptin) should NOT BE INITIATED in new patients